ArticleCureus2025
Right Ventricular Thrombus: A Rare but Potentially Fatal Condition.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Right ventricular thrombus (RVT) is a rare but potentially fatal entity, often representing a thrombus in transit with high risk for embolization and obstructive shock. Management is particularly complex in oncology patients, where anticoagulation and thrombolysis may be contraindicated. We present a 49-year-old woman with newly diagnosed, locally advanced urothelial carcinoma (T4N3M0), who developed a 3.0 × 2.2 cm mobile thrombus within the right ventricular outflow tract (RVOT), detected by transthoracic echocardiography and corroborated by contrast-enhanced chest CT. Her course was complicated by active vaginal bleeding, thrombocytopenia (platelets: 40-60 × 10⁹/L), and coagulopathy (international normalized ratio: 1.6), precluding anticoagulation or systemic thrombolysis. Catheter-directed thrombectomy with AngioVac (AngioDynamics Inc., Latham, NY) was attempted but was unsuccessful. Pathology confirmed a bland thrombus, excluding tumor invasion. Despite placement of an inferior vena cava (IVC) filter, she suffered obstructive shock with hypotension (systolic blood pressure: ~70 mmHg), hypoxemia (oxygen saturation: 70% on supplemental oxygen), and supraventricular tachycardia, requiring cardioversion, vasopressors, and intubation. Her condition further declined with extensive bilateral deep vein thromboses, methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.